Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$40.00
-0.9%
$33.85
$23.42
$62.58
$2.34B0.73657,481 shs824,551 shs
Indivior PLC stock logo
INDV
Indivior
$16.01
-0.9%
$13.49
$7.33
$16.34
N/A0.651.24 million shs1.54 million shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$11.25
-3.2%
$10.47
$7.44
$11.88
$581.01M-0.02257,811 shs144,416 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.17
-1.9%
$33.69
$27.12
$60.90
$2.15B2.41965,321 shs624,000 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-0.87%+2.43%+12.68%+44.61%-15.18%
Indivior PLC stock logo
INDV
Indivior
-0.93%+3.49%+15.18%+77.69%+48.65%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-3.18%-0.44%+5.93%+30.51%+13.75%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.90%-7.52%-2.01%-4.43%-37.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.3916 of 5 stars
3.43.00.04.32.30.81.9
Indivior PLC stock logo
INDV
Indivior
0.8458 of 5 stars
1.61.00.00.00.01.71.9
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
1.584 of 5 stars
3.30.00.00.01.12.50.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.21 of 5 stars
3.45.00.04.41.50.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6046.50% Upside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$17.006.18% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.67
Moderate Buy$16.6047.56% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4043.30% Upside

Current Analyst Ratings Breakdown

Latest TBPH, AGIO, TWST, and INDV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
6/27/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
6/17/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/2/2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.50M63.47N/AN/A$27.02 per share1.48
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.80 per share8.88($2.52) per shareN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$65.27M8.62N/AN/A$3.57 per share3.15
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.73N/AN/A$8.07 per share4.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.56N/AN/A1,798.26%-2.75%-2.52%7/31/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A9.36N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$56.42M-$1.18N/A32.14N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest TBPH, AGIO, TWST, and INDV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.12N/AN/AN/A$16.04 millionN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/31/2025Q2 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.74N/AN/AN/A$9.46 millionN/A
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/A$239.43 millionN/A
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.77
4.77
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Indivior PLC stock logo
INDV
Indivior
60.33%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
99.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.30%
Indivior PLC stock logo
INDV
Indivior
N/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
6.90%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.43 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
11050.00 million46.55 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$40.00 -0.35 (-0.87%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$40.29 +0.29 (+0.73%)
As of 07/18/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Indivior stock logo

Indivior NASDAQ:INDV

$16.01 -0.15 (-0.93%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$16.01 0.00 (0.00%)
As of 07/18/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$11.25 -0.37 (-3.18%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$11.24 -0.01 (-0.09%)
As of 07/18/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.17 -0.68 (-1.90%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$35.92 +0.74 (+2.12%)
As of 07/18/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.